AI Engines For more Details: Perplexity Kagi Labs You
Leprosy (Hansen's Disease): Dapsone is a key component of multidrug therapy for the treatment of leprosy. It is effective against Mycobacterium leprae, the bacteria that cause leprosy. Dapsone helps to control the symptoms of leprosy and prevent its spread to others.
Dermatitis Herpetiformis: Dapsone is also used to treat dermatitis herpetiformis, a chronic skin condition characterized by itchy, blistering skin lesions. Dapsone helps to reduce inflammation and suppress the autoimmune response associated with dermatitis herpetiformis.
Other Skin Conditions: Dapsone may be used off-label to treat various other skin conditions, including acne vulgaris, bullous pemphigoid, and linear IgA bullous dermatosis. Its anti-inflammatory and antibacterial properties make it effective in managing these skin disorders.
Pneumocystis Pneumonia (PCP): Dapsone is sometimes used as a prophylactic treatment to prevent Pneumocystis jirovecii pneumonia (formerly known as Pneumocystis carinii pneumonia or PCP) in individuals with weakened immune systems, such as those with HIV/AIDS.
Granulomatous Diseases: Dapsone may be used to treat granulomatous diseases such as granuloma annulare and sarcoidosis. Its anti-inflammatory properties help to suppress granuloma formation and reduce symptoms associated with these conditions.
Adverse Effects: Common side effects of dapsone include nausea, vomiting, headache, dizziness, and skin rash. It can also cause hemolytic anemia, particularly in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Other potential adverse effects include methemoglobinemia, peripheral neuropathy, and liver toxicity.
Monitoring: Patients taking dapsone may require regular monitoring of blood cell counts, liver function tests, and methemoglobin levels to detect and manage potential adverse effects. Close monitoring is especially important in individuals with G6PD deficiency or other risk factors for hemolytic anemia.
Drug Interactions: Dapsone may interact with other medications, including rifampicin, trimethoprim-sulfamethoxazole, and antiretroviral drugs used to treat HIV/AIDS. Healthcare providers should be aware of potential drug interactions and adjust medication doses as needed.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
Acne | 0.2 | -0.2 | |
ADHD | 1.6 | 0.4 | 3 |
Age-Related Macular Degeneration and Glaucoma | 0.3 | 0 | 0 |
Allergic Rhinitis (Hay Fever) | 0.4 | 1.2 | -2 |
Allergies | 2.6 | 0.8 | 2.25 |
Allergy to milk products | 0.6 | 0.5 | 0.2 |
Alopecia (Hair Loss) | 0.5 | 0.5 | |
Alzheimer's disease | 1.6 | 2.1 | -0.31 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.7 | 1.1 | 1.45 |
Ankylosing spondylitis | 1.8 | 0.5 | 2.6 |
Anorexia Nervosa | 0 | 0.8 | 0 |
Antiphospholipid syndrome (APS) | 0.9 | 0.2 | 3.5 |
Asthma | 0.6 | 1 | -0.67 |
Atherosclerosis | 0.3 | 0.9 | -2 |
Atrial fibrillation | 1.5 | 0.8 | 0.88 |
Autism | 3.3 | 4.7 | -0.42 |
Barrett esophagus cancer | 0.1 | 0.2 | -1 |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Biofilm | 0.6 | 0.6 | |
Bipolar Disorder | 0.6 | 0.6 | 0 |
Brain Trauma | 0.3 | 0.2 | 0.5 |
Cancer (General) | 0.2 | 1.5 | -6.5 |
Carcinoma | 1.8 | 1 | 0.8 |
Celiac Disease | 1.1 | 2.5 | -1.27 |
Cerebral Palsy | 0.7 | 0.4 | 0.75 |
Chronic Fatigue Syndrome | 2.3 | 3 | -0.3 |
Chronic Kidney Disease | 0.7 | 0.7 | 0 |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.7 | -0.17 |
Chronic Urticaria (Hives) | 1.1 | 0.6 | 0.83 |
Coagulation / Micro clot triggering bacteria | 1 | 0.5 | 1 |
Colorectal Cancer | 1.9 | 0.3 | 5.33 |
Constipation | 0.7 | 0.3 | 1.33 |
Coronary artery disease | 0 | 0.5 | 0 |
COVID-19 | 5 | 5.5 | -0.1 |
Crohn's Disease | 2.9 | 2.7 | 0.07 |
cystic fibrosis | 0.8 | 0.4 | 1 |
deep vein thrombosis | 0.8 | 0.3 | 1.67 |
Depression | 4.3 | 3.3 | 0.3 |
Dermatomyositis | 0.2 | 0.2 | 0 |
Eczema | 0.4 | 0.9 | -1.25 |
Endometriosis | 1.9 | 0.6 | 2.17 |
Eosinophilic Esophagitis | 0.1 | -0.1 | |
Epilepsy | 1.4 | 1.3 | 0.08 |
Fibromyalgia | 0.7 | 0.7 | 0 |
Functional constipation / chronic idiopathic constipation | 2.6 | 1.1 | 1.36 |
gallstone disease (gsd) | 0.8 | 0.3 | 1.67 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.6 | -2 |
Generalized anxiety disorder | 1.1 | 1.2 | -0.09 |
Glioblastoma | 0.2 | -0.2 | |
Gout | 0.2 | -0.2 | |
Graves' disease | 0.4 | 0.5 | -0.25 |
Halitosis | 0.2 | 0.2 | 0 |
Hashimoto's thyroiditis | 1.2 | 0.5 | 1.4 |
Hidradenitis Suppurativa | 0.4 | 0.1 | 3 |
High Histamine/low DAO | 0.7 | 0.2 | 2.5 |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.5 | -1.5 |
hyperglycemia | 0.4 | 1.3 | -2.25 |
Hyperlipidemia (High Blood Fats) | 0.5 | 0 | 0 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 1.1 | 2.9 | -1.64 |
Hypothyroidism | 0.8 | -0.8 | |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 1.1 | -1.1 | |
Inflammatory Bowel Disease | 2.2 | 3 | -0.36 |
Insomnia | 0.5 | 0.5 | 0 |
Intelligence | 0.2 | 0.2 | |
Intracranial aneurysms | 0.3 | 0 | 0 |
Irritable Bowel Syndrome | 2.1 | 1.5 | 0.4 |
Liver Cirrhosis | 2.2 | 1.5 | 0.47 |
Long COVID | 3.2 | 4 | -0.25 |
Low bone mineral density | 0.7 | -0.7 | |
Lung Cancer | 0.6 | 0.9 | -0.5 |
Mast Cell Issues / mastitis | 0.5 | 0.4 | 0.25 |
ME/CFS with IBS | 0.5 | 1.5 | -2 |
ME/CFS without IBS | 0.8 | 0.9 | -0.13 |
Menopause | 1.1 | 1.1 | |
Metabolic Syndrome | 3.4 | 3.8 | -0.12 |
Mood Disorders | 5.4 | 3.5 | 0.54 |
multiple chemical sensitivity [MCS] | 0.9 | 0.2 | 3.5 |
Multiple Sclerosis | 3.5 | 1.2 | 1.92 |
Multiple system atrophy (MSA) | 1 | 0.4 | 1.5 |
neuropathic pain | 1.1 | -1.1 | |
Neuropathy (all types) | 0.6 | 0.3 | 1 |
neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 3.2 | -2.56 |
NonCeliac Gluten Sensitivity | 1.2 | 0.3 | 3 |
Obesity | 3.5 | 2.3 | 0.52 |
obsessive-compulsive disorder | 2.3 | 1.7 | 0.35 |
Osteoarthritis | 0.7 | 0.7 | |
Osteoporosis | 0.6 | 0.8 | -0.33 |
pancreatic cancer | 0.4 | 0.4 | |
Parkinson's Disease | 3.8 | 2.1 | 0.81 |
Polycystic ovary syndrome | 0.6 | 0.8 | -0.33 |
Postural orthostatic tachycardia syndrome | 0.4 | -0.4 | |
Premenstrual dysphoric disorder | 0.5 | 0 | 0 |
primary biliary cholangitis | 0.2 | 0 | 0 |
Psoriasis | 2.1 | 0.9 | 1.33 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.6 | 1.2 | 1.17 |
Rosacea | 0.3 | 0.1 | 2 |
Schizophrenia | 3.2 | 0.7 | 3.57 |
scoliosis | 0.2 | 1 | -4 |
Sjögren syndrome | 1.1 | 1 | 0.1 |
Sleep Apnea | 0.6 | 0.8 | -0.33 |
Slow gastric motility / Gastroparesis | 0.7 | 0.2 | 2.5 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.7 | 0 |
Stress / posttraumatic stress disorder | 1.4 | 1.6 | -0.14 |
Systemic Lupus Erythematosus | 1.7 | 1.1 | 0.55 |
Tic Disorder | 0.2 | 0.5 | -1.5 |
Tourette syndrome | 0.3 | 0.1 | 2 |
Type 1 Diabetes | 1.3 | 0.9 | 0.44 |
Type 2 Diabetes | 3.4 | 2.9 | 0.17 |
Ulcerative colitis | 1.8 | 1.9 | -0.06 |
Unhealthy Ageing | 1.6 | 1 | 0.6 |
Vitiligo | 0.9 | 0.9 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.80.143 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.80.143 ]